Herpesvirus 4, Human

"Herpesvirus 4, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.

Descriptor ID	D004854
MeSH Number(s)	B04.280.210.400.500.450 B04.280.382.400.500.400 B04.613.204.500.500.400
Concept/Terms	Herpesvirus 4, Human Herpesvirus 4, Human Burkitt Lymphoma Virus Lymphoma Virus, Burkitt Burkitt's Lymphoma Virus Burkitts Lymphoma Virus E-B Virus E B Virus E-B Viruses Infectious Mononucleosis Virus Infectious Mononucleosis Viruses Mononucleosis Virus, Infectious Mononucleosis Viruses, Infectious Epstein-Barr Virus Epstein Barr Virus Herpesvirus 4 (gamma), Human HHV-4 Human Herpesvirus 4 Burkitt Herpesvirus Herpesvirus, Burkitt EBV

Below are MeSH descriptors whose meaning is more general than "Herpesvirus 4, Human".

Organisms [B]
Viruses [B04]
DNA Viruses [B04.280]
DNA Tumor Viruses [B04.280.210]
Gammaherpesvirinae [B04.280.210.400]
Lymphocryptovirus [B04.280.210.400.500]
Herpesvirus 4, Human [B04.280.210.400.500.450]
Herpesviridae [B04.280.382]
Gammaherpesvirinae [B04.280.382.400]
Lymphocryptovirus [B04.280.382.400.500]
Herpesvirus 4, Human [B04.280.382.400.500.400]
Oncogenic Viruses [B04.613]
DNA Tumor Viruses [B04.613.204]
Gammaherpesvirinae [B04.613.204.500]
Lymphocryptovirus [B04.613.204.500.500]
Herpesvirus 4, Human [B04.613.204.500.500.400]

Below are MeSH descriptors whose meaning is related to "Herpesvirus 4, Human".

Below are MeSH descriptors whose meaning is more specific than "Herpesvirus 4, Human".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Herpesvirus 4, Human" by people in this website by year, and whether "Herpesvirus 4, Human" was a major or minor topic of these publications.

Bar chart showing 114 publications over 30 distinct years, with a maximum of 7 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	1	2
1996	3	1	4
1997	2	0	2
1998	2	1	3
1999	4	0	4
2000	1	3	4
2002	3	1	4
2003	3	1	4
2004	2	1	3
2005	4	2	6
2006	1	1	2
2007	6	0	6
2008	2	0	2
2009	1	3	4
2010	5	1	6
2011	1	0	1
2012	4	1	5
2013	5	0	5
2014	5	0	5
2015	4	1	5
2016	5	0	5
2017	2	2	4
2018	1	1	2
2019	3	1	4
2020	2	1	3
2021	1	4	5
2022	0	4	4
2023	2	5	7
2024	1	0	1
2025	2	0	2

Below are the most recent publications written about "Herpesvirus 4, Human" by people in Profiles.

Kim IE, Fola AA, Puig E, Maina TK, Hui ST, Ma H, Zuckerman K, Agwati EO, Leonetti A, Crudale R, Luftig MA, Moormann AM, Oduor C, Bailey JA. Comparison of nanopore with illumina whole genome assemblies of the Epstein-Barr virus in Burkitt lymphoma. Sci Rep. 2025 Mar 31; 15(1):10970.

View in: PubMed
Kim IE, Oduor C, Stamp J, Luftig MA, Moormann AM, Crawford L, Bailey JA. Incorporation of Epstein-Barr viral variation implicates significance of Latent Membrane Protein 1 in survival prediction and prognostic subgrouping in Burkitt lymphoma. Int J Cancer. 2025 Jun 01; 156(11):2188-2199.

View in: PubMed
Escalante GM, Reidel IG, Mutsvunguma LZ, Cua S, Tello BA, Rodriguez E, Farelo MA, Zimmerman C, Muniraju M, Li H, Govindan AN, Axthelm MK, Wong SW, Ogembo JG. Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice. Front Immunol. 2024; 15:1445209.

View in: PubMed
Bose A, Khalighinejad F, Hoaglin DC, Hemond CC. Evaluating the Clinical Utility of Epstein-Barr Virus Antibodies as Biomarkers in Multiple Sclerosis: A Systematic Review. Mult Scler Relat Disord. 2024 Apr; 84:105410.

View in: PubMed
Willard KA, Barry AP, Oduor CI, Ong'echa JM, Bailey JA, Moormann AM, Luftig MA. Viral and host factors drive a type 1 Epstein-Barr virus spontaneous lytic phenotype. mBio. 2023 Dec 19; 14(6):e0220423.

View in: PubMed
Muriuki BM, Forconi CS, Kirwa EK, Maina TK, Ariera BO, Bailey JA, Ghansah A, Moormann AM, Ong'echa JM. Evaluation of KIR3DL1/KIR3DS1 allelic polymorphisms in Kenyan children with endemic Burkitt lymphoma. PLoS One. 2023; 18(8):e0275046.

View in: PubMed
L?tgehetmann M, Albert E, Hamilton A, Jarem D, Pfefferle S, Stucki H, Navarro D. Evaluation of a Quantitative Dual-Target EBV DNA Test on a Fully Automated Molecular Testing System. J Clin Microbiol. 2023 08 23; 61(8):e0051823.

View in: PubMed
Oluoch PO, Forconi CS, Oduor CI, Ritacco DA, Akala HM, Bailey JA, Juliano JJ, Ong'echa JM, M?nz C, Moormann AM. Distinctive Kaposi Sarcoma-Associated Herpesvirus Serological Profile during Acute Plasmodium falciparum Malaria Episodes. Int J Mol Sci. 2023 Apr 04; 24(7).

View in: PubMed
Saikumar Lakshmi P, Oduor CI, Forconi CS, M'Bana V, Bly C, Gerstein RM, Otieno JA, Ong'echa JM, M?nz C, Luftig MA, Brehm MA, Bailey JA, Moormann AM. Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. Life Sci Alliance. 2023 05; 6(5).

View in: PubMed
Clark F, Gil A, Thapa I, Aslan N, Ghersi D, Selin LK. Cross-reactivity influences changes in human influenza A virus and Epstein Barr virus specific CD8 memory T cell receptor alpha and beta repertoires between young and old. Front Immunol. 2022; 13:1011935.

View in: PubMed

People

Explore

Similar Concepts

Top Journals